MedPath

Zinc acetate

Generic Name
Zinc acetate
Brand Names
Banophen, Benadryl Itch Stopping, Caladryl Clear, Derma Gran, Galzin, Wal-dryl
Drug Type
Small Molecule
Chemical Formula
C4H6O4Zn
CAS Number
557-34-6
Unique Ingredient Identifier
H2ZEY72PME
Indication

Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections .

Associated Conditions
Pruritus, Skin Irritation, Oozing and weeping, Pain and itching
Clinical Trials
Related News

ESTEVE Acquires Global Rights to Increlex for Rare Growth Disorder Treatment

• ESTEVE has signed a licensing agreement with Eton Pharmaceuticals for global rights to Increlex®, a biologic treatment for severe primary insulin-like growth factor-1 deficiency (SPIGFD), excluding the US market. • The acquisition aligns with ESTEVE's strategic focus on specialized treatments for high unmet medical needs, marking the company's first biologic product in its portfolio. • Increlex® is approved for treating growth failure in children and adolescents aged 2-18 years with SPIGFD, a rare condition where patients have low levels of IGF-1 hormone essential for normal growth.

Eton Pharmaceuticals Poised for Growth with Expanding Rare Disease Portfolio and Pending FDA Approvals

• Eton Pharmaceuticals is anticipating FDA approval for ET-400 in early June, with commercial launch planned immediately following approval and significant revenue impact expected in Q3 and Q4 2025. • The company has successfully relaunched Increlex for growth disorders, reaching over 90 patients, and Galzin for Wilson disease, with improved patient access and a $0 co-pay program. • Eton is pursuing label expansion for Increlex based on European patient registry data, with an FDA meeting expected in July and submission planned for Q3 2025.

Eton Pharmaceuticals' ET-600 Meets Bioequivalence Endpoints for Central Diabetes Insipidus Treatment

• Eton Pharmaceuticals' ET-600, a patented desmopressin oral solution, successfully demonstrated pharmacokinetic equivalence to the FDA-approved reference product in a pivotal study with 75 subjects. • The company plans to submit a New Drug Application to the FDA in April 2025, positioning ET-600 to potentially become the only FDA-approved oral liquid formulation of desmopressin. • If approved, ET-600 would address a significant unmet need for pediatric patients with central diabetes insipidus who require precise, titratable dosing, with potential market launch in Q1 2026.

Eton Pharmaceuticals Launches FDA-Approved Galzin for Wilson Disease Maintenance Treatment

• Eton Pharmaceuticals has launched Galzin (zinc acetate) capsules, the only FDA-approved zinc therapy for Wilson disease maintenance treatment, offering improved access through their specialty pharmacy network. • The company introduces the Eton Cares Program, providing $0 co-pay for eligible patients and comprehensive support services, addressing historic availability and affordability challenges. • Through partnership with Optime Care specialty pharmacy, Eton aims to enhance treatment accessibility while investing in research for advancing Wilson disease therapeutics.

FDA Extends Review Period for Eton Pharmaceuticals' Rare Disease Drug ET-400

• The FDA has extended the PDUFA goal date for Eton Pharmaceuticals' ET-400 New Drug Application to May 28, 2025, requiring additional time to review supplemental information. • Eton Pharmaceuticals maintains confidence in their NDA package and does not expect the three-month extension to significantly impact their 2025 revenue projections. • The company, focused on rare disease treatments, currently markets seven commercial products and has four additional candidates in late-stage development.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy